Price$0.52+0.06 (+12.20%)
01:30 PM05:45 PM
News · 26 weeks38+33%
2025-12-072026-05-31
Mix1790d
- SEC Filings7(41%)
- Insider6(35%)
- Other3(18%)
- Dividends1(6%)
Latest news
25 items- SECSEC Form D filed by BNB Plus Corp.D - BNB PLUS CORP. (0000744452) (Filer)
- SECBNB Plus Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BNB PLUS CORP. (0000744452) (Filer)
- PRBNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic FinancingSilvermine Capital Leads New and Existing Investor Group in Partnership with GlobalStake to Support Strategic Review of Digital Asset and Biotechnology Businesses Additional Commitments Expected with the Company Targeting $5M in Total Proceeds BNB Plus Corp. (NASDAQ:BNBX) ("BNB Plus" or the "Company"), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5.0M (the "Financing"). Proceeds from the Financing will be used to bolster the Company's digital asset treasury and will provide working capital in support of a comprehensive strategic review. With the anticipated proce
- SECSEC Form 10-Q filed by BNB Plus Corp.10-Q - BNB PLUS CORP. (0000744452) (Filer)
- SECBNB Plus Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BNB PLUS CORP. (0000744452) (Filer)
- PRBNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ OrderBNB Plus Corp. (NASDAQ:BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed production of its largest order in LineaRx history. The $1.2 million order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically higher margins with zero batch failures, demonstrating the technical excellence and manufacturing reliability of the LineaDNA platform for large-scale cell-free DNA production. Notably, the Company achieved a production cadence of more than 1.5 grams per week during fulfillment of this order, a new record for LineaRx and a further demonstr
- PRBNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder ValueCompany Treasury Exceeds $12 Million with Recently Implemented Active Yield Generation Strategy Provides Nasdaq Listing Status Update BNB Plus Corp. (NASDAQ:BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update on its Nasdaq listing status. Strategic Review and Treasury Value The strategic alternatives under consideration include, but are not limited to, a merger, reverse merger, business combination, acquisition, asset sale, joint venture, additional capital raisin
- INSIDERSEC Form 4 filed by Shamash Yacov A4 - BNB PLUS CORP. (0000744452) (Issuer)
- INSIDERSEC Form 4 filed by Catell Robert B4 - BNB PLUS CORP. (0000744452) (Issuer)
- INSIDERSEC Form 4 filed by Murrah Judith4 - BNB PLUS CORP. (0000744452) (Issuer)
- INSIDERSEC Form 4 filed by Ceccoli Joseph D.4 - BNB PLUS CORP. (0000744452) (Issuer)
- INSIDERSEC Form 4 filed by Kruger Joshua4 - BNB PLUS CORP. (0000744452) (Issuer)
- INSIDERSEC Form 4 filed by Haft James4 - BNB PLUS CORP. (0000744452) (Issuer)
- SECSEC Form DEF 14A filed by BNB Plus Corp.DEF 14A - BNB PLUS CORP. (0000744452) (Filer)
- SECBNB Plus Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - BNB PLUS CORP. (0000744452) (Filer)
- PRBNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT PlatformPatent Covers the Composition of LineaRx's Proprietary Linea™ RNA Polymerase (RNAP), a Core Technology Empowering the Linea™ IVT Platform BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (RNAP) enzyme branded Linea RNAP. The Company plans to validate the patent in key Europ
- SECSEC Form PRE 14A filed by BNB Plus Corp.PRE 14A - BNB PLUS CORP. (0000744452) (Filer)
- PRBNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine DevelopersProvides Updated on BNB Token Holdings and Operating Company Performance BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies," said Clay Shorrock, President and CEO of BNBX. "We believe our continued engagements with top-tier customers demonstrates both the technical excellence of our LineaDNA platform and our continued operational execution.
- INSIDERSEC Form 4 filed by Director Haft James4 - BNB PLUS CORP. (0000744452) (Issuer)
- INSIDERNew insider Haft James claimed ownership of 22,590 shares (SEC Form 3)3 - BNB PLUS CORP. (0000744452) (Issuer)
- SECSEC Form SCHEDULE 13G filed by BNB Plus Corp.SCHEDULE 13G - BNB PLUS CORP. (0000744452) (Subject)
- SECSEC Form 10-Q filed by BNB Plus Corp.10-Q - BNB PLUS CORP. (0000744452) (Filer)
- SECBNB Plus Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BNB PLUS CORP. (0000744452) (Filer)
- PRBNB Plus Corp. (BNBX) Appoints James Haft as Independent Board DirectorDigital Asset and Infrastructure Expert Joins Board to Support Strategic Growth and BNB Treasury Operations BNB Plus Corp. (NASDAQ:BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear Stearns Inc, Furman Selz and ING Barings, where he focused on emerging markets, and founded and served as chairman
- SECSEC Form S-8 filed by BNB Plus Corp.S-8 - BNB PLUS CORP. (0000744452) (Filer)
BNBX FAQ
4 questionsWhere does BNBX stock trade?
BNB Plus Corp. (BNBX) is listed on NASDAQ.What sector and industry is BNBX in?
BNB Plus Corp. operates in the Consumer Discretionary sector, Other Consumer Services industry.What companies are similar to BNBX?
Notable peers in the same industry include BAM (Brookfield Asset Management Inc), SE (Sea Limited), EDU (New Oriental Education & Technology Group Inc. Sponsored ADR r), IT (Gartner Inc.), SCI (Service Corporation International). Compare BNBX side-by-side with any of them on Quantisnow.How can I track BNBX on Quantisnow?
Quantisnow aggregates BNB Plus Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BNBX to receive live email and push alerts on every new disclosure.